Nordicus Partners Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $78.0M
- Price
- $4.01
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.74%
- Volume
- 43.6K
About
Nordicus Partners Corporation functions as a publicly traded entity that acts as both a business accelerator and a holding company, specifically supporting Nordic life sciences firms operating within the United States. A central focus for the company involves advancing oral healthcare through the development of new medicines. In addition to its core operations, Nordicus offers an array of corporate finance and advisory services. These include aiding in business and market expansion, formulating strategic growth plans, identifying and acquiring talent, fostering key partnerships, facilitating capital raising efforts, and orchestrating company acquisitions or sales. The organization, which was established in 1993 and is headquartered in Beverly Hills, California, rebranded as Nordicus Partners Corporation in May 2023, having previously been known as EKIMAS Corporation.
Quick stats
Shares outstanding19.4M
Computed float6.1M
Float / shares31.2%
Key info
SectorIndustrials
IndustryConsulting Services
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001011060
Websitehttps://nordicuspartners.com
AI Summary
AI-generated1/3
minorbullishboard change
Nordicus Partners Corporation Appoints Elizabeth Addonizio to Its Board of Directors
Nordicus Partners Corporation appointed Elizabeth Addonizio as an independent member of its Board of Directors, effective September 1, 2026, strengthening board independence and financial expertise.
Addonizio brings 25 years of finance experience spanning venture and private equity investing and investment banking, including advising on more than $25 billion in transactions at Morgan Stanley; she also serves as a board-selected commanding officer in the U.S. Navy Reserve.
CEO Henrik Rouf framed the hire as supporting the company as it advances QR-01 and QR-02 toward clinical trials and continues to pursue an uplisting to a major national exchange, where governance depth and access to institutional capital are prerequisites.
Red flags
- uplisting to a major national exchange is forward-looking and not assured
- pipeline assets QR-01 and QR-02 remain preclinical; no clinical or financial data disclosed
- OTCQB micro-cap with no financial figures in the release